Beam Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
BEAM$25.15-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(324,289) | $(286,388) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 16,626 | 16,482 |
| Amortization of investment discount (premiums) | (12,700) | (18,125) |
| In-process research and development charge | 14,507 | — |
| Stock-based compensation expense | 73,796 | 90,444 |
| Change in operating lease right-of-use assets | 7,870 | 7,193 |
| Change in fair value of derivative liabilities | (650) | (2,400) |
| Change in fair value of contingent consideration liabilities | (945) | (1,619) |
| Change in fair value of non-controlling equity investments | (7,271) | 13,003 |
| Realized loss (gain) on sale of marketable securities | 399 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,452 | 2,458 |
| Accounts payable | 4,846 | 2,357 |
| Accrued expenses and other liabilities | (6,613) | (53,610) |
| Operating lease liabilities | (10,005) | (9,676) |
| Deferred revenue | (21,597) | (31,451) |
| Other long-term liabilities | (239) | 451 |
| Net cash provided by (used in) operating activities | (261,813) | (270,881) |
| Investing activities | ||
| Purchases of property and equipment | (11,212) | (5,976) |
| Purchases of marketable securities | (848,754) | (486,439) |
| Maturities of marketable securities | 624,456 | 551,142 |
| Proceeds from sale of marketable securities | 5,743 | — |
| Cash paid for acquisition, net | (78) | — |
| Net cash provided by (used in) investing activities | (229,845) | 58,727 |
| Financing activities | ||
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | 470,513 | — |
| Proceeds from issuances of stock under ESPP | 2,764 | 2,622 |
| Repayment of equipment financings | — | (485) |
| Proceeds from exercise of stock options | 2,886 | 2,155 |
| Net cash provided by (used in) financing activities | 476,163 | 4,292 |
| Net change in cash, cash equivalents and restricted cash | (15,495) | (207,862) |
| Cash, cash equivalents and restricted cash—beginning of period | 290,111 | 444,614 |
| Cash, cash equivalents and restricted cash—end of period | $274,616 | $236,752 |
Condensed Consolidated Statements of Cash Flows - Continued
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $32 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Property and equipment additions in accounts payable and accrued expenses | $3,126 | $451 |
| Operating lease liabilities arising from obtaining right-of-use assets | $— | $(1,010) |
| Contingent consideration liabilities assumed in acquisition | $7,715 | $— |
| Fair value of equity instruments issued in connection with acquisition | $6,715 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.